Unknown

Dataset Information

0

Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.


ABSTRACT: The emergence of SARS-CoV-2 virus has resulted in a worldwide pandemic, but effective antiviral therapies are not widely available. To improve treatment options, we conducted a high-throughput screen to uncover compounds that block SARS-CoV-2 infection. A minimally pathogenic human betacoronavirus (OC43) was used to infect physiologically-relevant human pulmonary fibroblasts (MRC5) to facilitate rapid antiviral discovery in a preclinical model. Comprehensive profiling was conducted on more than 600 compounds, with each compound arrayed across 10 dose points. Our screening revealed several FDA-approved agents that can attenuate both OC43 and SARS-CoV-2 viral replication, including lapatinib, doramapimod, and 17-AAG. Importantly, lapatinib inhibited SARS-CoV-2 RNA replication by over 50,000-fold. Further, both lapatinib and doramapimod could be combined with remdesivir to improve antiviral activity in cells. These findings reveal novel therapeutic avenues that could limit SARS-CoV-2 infection.

SUBMITTER: Raymonda MH 

PROVIDER: S-EPMC8626825 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-SCDT-10_1038-S44319-024-00189-4 | biostudies-other
| S-EPMC7481761 | biostudies-literature
2024-08-14 | GSE274550 | GEO
| S-EPMC10222355 | biostudies-literature
| S-EPMC9031298 | biostudies-literature
| S-EPMC8402645 | biostudies-literature
| S-EPMC8251057 | biostudies-literature
| S-EPMC10142420 | biostudies-literature
| S-EPMC9199336 | biostudies-literature
| S-EPMC10288389 | biostudies-literature